Liraglutide
Also known as: Victoza · Saxenda
An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes and weight management. Produces 5-8% average weight loss with established cardiovascular safety data.
Mechanism of Action
Liraglutide is a 97% homologous GLP-1 analog with a fatty acid side chain that enables once-daily dosing. It activates GLP-1 receptors to slow gastric emptying and reduce appetite.
Benefits
- FDA-approved for weight management
- Reduces appetite and caloric intake
- 5-8% average weight reduction
- Improved glycemic control
- Cardiovascular safety established
- Once-daily dosing
Side Effects & Risks
- Nausea (very common)
- Diarrhea
- Constipation
- Vomiting
- Injection site reactions
- Potential gallbladder disease
Where to Buy Liraglutide
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$48.00
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies1 trial
SCALE Obesity and Prediabetes: Liraglutide 3mg for Weight Management
In 3,731 adults with obesity (without T2D), liraglutide 3mg produced mean weight loss of 8.4 kg (-8.0%) vs 2.8 kg (-2.6%) placebo at 56 weeks (p<0.001). 63.2% vs 27.1% achieved ≥5% loss.
Primary Outcome
Weight change at 56 weeks
p-value
<0.001
Placebo
-2.8 kg (-2.6%)
≥5% Responders
63.2% vs 27.1%
Liraglutide 3mg
-8.4 kg (-8.0%)
≥10% Responders
33.1% vs 10.6%
Molecular Structure
- CAS Number
- 204656-20-2
- PubChem CID
- 16134956
- Molecular Weight
- 3,751 Da
- Mol. Formula
- C172H265N43O51
- Amino Acids
- 31-AA peptide
- Wikipedia
- View article
Research Protocol
- Dose Range
- 0.6–3 mg
- Frequency
- Once daily subcutaneous injection
- Cycle
- Ongoing / chronic
- Half-Life
- 13 hours
- Routes
- subcutaneous injection
- Notes
- Start at 0.6mg/day, titrate weekly to target of 1.8mg or 3mg.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
External Resources
More in Weight Management
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.